Why did ADIL's EPS stay flat in Q3 2023?

The EPS of ADIL remained flat in Q3 2023 due to several factors:

1. **Regulatory Focus and Strategic Planning**: ADIL has been focused on regaining Nasdaq compliance and has undergone a reverse stock split to address the minimum bid price requirement. This strategic move indicates a concentration on stabilizing the stock's market position rather than expanding operations or increasing production, which might have impacted earnings.
2. **Clinical Trial Progress**: ADIL's lead investigational new drug product, AD04, has been in a pivotal Phase 3 clinical trial for the treatment of Alcohol Use Disorder (AUD). The company has recently reached 35% enrollment in this trial. Clinical trials are significant endeavors that require substantial resources, including financial investments, which can affect the company's net income. The ongoing and upcoming costs associated with these trials might have offset potential earnings improvements.

In conclusion, ADIL's flat EPS in Q3 2023 can be attributed to a combination of regulatory focus and strategic planning, and the ongoing clinical trials for AD04.

|code|Ticker|Name|Date|Diluted EPS YoY|Diluted EPS|market_code|
|---|---|---|---|---|---|---|
|ADIL|ADIL.O|Adial|2023 Q1|-2015.3846153846152|-2.75|186|
|ADIL|ADIL.O|Adial|2023 Q2|124.49494949494948|0.97|186|
|ADIL|ADIL.O|Adial|2023 Q3|60.9271523178808|-1.18|186|